Avidity Biosciences stock: Roth Capital sets a USD 15.00 target

Published on 10/24/2026 at 05:09 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Roth Capital set a USD 15.00 target on October 22, 2026. Avidity Biosciences stock reported Q2 revenue of USD 3.00 million versus USD 0.67 million consensus.

Analyst target and reporting date

Roth Capital initiated coverage with a Buy rating and a USD 15.00 target on October 22, 2026.
Avidity reported USD 3.00 million in second-quarter revenue versus USD 0.67 million consensus.
MarketBeat lists November 12, 2026 as the estimated third-quarter reporting date.

RNA, US05370A1088, Illustration mit AI erstellt.

Avidity Biosciences (ISIN US05370A1088) received a Buy rating and a USD 15.00 price target from Roth Capital on October 22, 2026, according to MarketBeat. The report placed the analyst view against a clinical-stage biotechnology company developing antibody oligonucleotide conjugates for rare muscle diseases.

Roth Capital sets a USD 15.00 target

Roth Capital initiated coverage with a Buy rating and a USD 15.00 target, while the same report described a broader Hold consensus. The target and rating are dated October 22, 2026, giving investors a clearly defined analyst reference for the company after a period of sharp research attention.

The target is an analyst opinion rather than company guidance. Avidity's platform combines antibody targeting with oligonucleotide medicines intended to act on RNA inside specific cells, according to the company's corporate description.

What did the second quarter deliver?

The latest reported quarter supplied a stronger revenue comparison than the consensus figure. Avidity generated USD 3.00 million in second-quarter revenue versus USD 0.67 million expected, while adjusted earnings per share were not used here because the source reports the figure as a quarterly loss of USD 1.18 per share against a USD 1.42 consensus loss, according to MarketBeat.

Three dates frame the story

On February 27, 2026, Novartis completed its acquisition of Avidity Biosciences for USD 72.00 per share, according to Investing.com. On August 13, 2026, the company reported its second-quarter figures. On October 22, 2026, Roth Capital initiated coverage with the USD 15.00 target.

MarketBeat lists November 12, 2026 as the estimated date for third-quarter results and November 13, 2026 at 4:00 p.m. ET for the related conference call, with both dates subject to change.

RNA platform remains the central issue

Avidity's investment case centers on whether its AOC platform can translate targeted RNA delivery into approved medicines for serious muscle diseases. The October 22 analyst report ties its USD 15.00 target to that development story, while the second-quarter revenue comparison supplies the latest quantified operating context.

Company facts and next dates

Avidity Biosciences is a healthcare biotechnology company developing antibody oligonucleotide conjugates, with its corporate base in San Diego, California. The next dated company milestone listed by MarketBeat is the estimated third-quarter report on November 12, 2026.